medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 1

<< Back Next >>

MEDICC Review 2021; 23 (1)

Short-Term Tolerance of Nasally-Administered NeuroEPO in Patients with Parkinson Disease

García-Llano M, Pedroso-Ibáñez I, Morales-Chacón L, Rodríguez-Obaya T, Pérez-Ruiz L, Sosa-Testé I, Amaro GD, Bringas-Vega ML

Language: English
References: 36
Page: 49-54
PDF size: 164.25 Kb.


ABSTRACT

INTRODUCTION No neuroprotective treatment has been able to successfully halt the progression of Parkinson disease or prevent development of associated complications. Recombinant erythropoetin (EPO), an erythropoiesis-stimulating agent originally indicated in anemia, produced and manufactured in Cuba (iorEPOCIM, CIMAB S.A, Havana, Cuba) has neuroprotective properties. NeuroEPO is a new nasal formulation of recombinant EPO with a low content of sialic acid and without hematopoietic effects. It has neuroprotective effects in animal models.
OBJECTIVE Evaluate short-term tolerance of intranasal NeuroEPO in patients with Parkinson disease.
METHODS As part of a monocentric randomized placebo-controlled double-blind study (registered at www.clinicaltrials.gov number NCT04110678), 26 patients with Parkinson disease (stages 1 and 2 on Hoehn & Yahr Scale), were randomly divided into two groups: NeuroEPO (n = 15) and placebo (n = 11), both treated intranasally either with the drug (1 mL, at a concentration of 1 mg/mL of NeuroEPO) or placebo once a week for 5 weeks. At each application, we recorded any adverse events and blood pressure. To assess potential hematopoietic effects of the drug, hematological and biochemical variables were evaluated one week before and one week after the intervention.
RESULTS There were no signifi cant differences (p = 0.22) between the two groups in terms of frequency of adverse events (20.0% in NeuroEPO and 9.1% in placebo groups). Three patients in NeuroEPO presented nausea, and one vomited (possibly due to the patient’s positioning during drug application). One patient in placebo group reported polyuria and nasal irritation. In both groups, the adverse events were mild, brief, required no treatment and did not present sequelae.
CONCLUSION Nasally administered NeuroEPO for fi ve weeks in patients with Parkinson disease stages 1 and 2 on Hoehn & Yahr Scale is well tolerated.


REFERENCES

  1. Leverenz JB, Quinn JF, Zabetian C, Zhang J, Montine K, Montine T. Cognitive impairment and dementia in patients with Parkinson disease. Curr Top Med Chem. 2009;9(10):903–12.

  2. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov 1;17(11):939– 53.

  3. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 Mar–Apr;24(2):197–211.

  4. Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson’s disease. N Engl J Med. 2005 Sep 8;353(10):1021–7.

  5. Toba H, Kojima Y, Wang J, Noda K, Tian W, Kobara M, et al. Erythropoietin attenuated vascular dysfunction and infl ammation by inhibiting NADPH oxidase-derived superoxide production in nitric oxide synthase-inhibited hypertensive rat aorta. Eur J Pharmacol. 2012 Sep;691(1–3):190–7.

  6. Ge XH, Zhu GJ, Geng DQ, Zhang ZJ, Liu CF. Erythropoietin attenuates 6-hydroxydopamineinduced apoptosis via glycogen synthase kinase 3beta-mediated mitochondrial translocation of Bax in PC12 cells. Neurol Sci. 2012 Dec;33(6):1249–56.

  7. Liu P, Liu X, Liou AK, Xing J, Jing Z, Ji X, et al. The neuroprotective mechanism of erythropoietin- TAT fusion protein against neurodegeneration from ischemic brain injury. CNS Neurol Disord Drug Targets. 2014;13(8):1465–74.

  8. Ugurluer G, Cebi A, Mert H, Mert N, Serin M, Erkal HS. Neuroprotective effects of erythropoietin against oxidant injury following brain irradiation: an experimental study. Arch Med Sci. 2016 Dec 1;12(6):1348–53.

  9. Bond WS, Rex TS. Evidence that erythropoietin modulates neuroinfl ammation through differential action on neurons, astrocytes, and microglia. Front Immunol. 2014 Oct 24;5:523.

  10. Maiese K, Chong ZZ, Shang YC, Wang S. Erythropoietin: new directions for the nervous system. Int J Mol Sci. 2012;13(9):11102–29.

  11. Erbas O, Cinar BP, Solmaz V, Çavuşoğlu T, Ates U. The neuroprotective effect of erythropoietin on experimental Parkinson model in rats. Neuropeptides. 2015 Feb;49:1–5.

  12. FARMACODIVULGACION: Eritropoyetina humana recombinante. Rev Cubana Farm. 2012 Apr– Jun;46(2):287–8. Spanish.

  13. Santos-Morales O, Díaz-Machado A, Jiménez- Rodríguez D, Pomares-Iturralde Y, Festery- Casanovas T, González-Delgado CA, et al. Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open level safety study. BMC Neurol. 2017 Jul 4;17(1):129.

  14. Hoehn MM & Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427–27.

  15. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry.1992 Mar;55(3):181–4.

  16. Pedroso I, Bringas ML, Aguiar A, Morales L, Álvarez M, Valdés PA. Use of Cuban recombinant human erythropoietin in Parkinson’s disease treatment. MEDICC Rev. 2012 Jan;14(1):11–7.

  17. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martínez-Martín P, et al. Movement Disorder Society-sponsored revision of the Unifi ed Parkinson’s Disease Rating Scale (MDSUPDRS): scale presentation and clinometric testing results. Move Disord. 2008 Nov 15;23(15):2129–70.

  18. Folstein M, Robins N, Helzer, J. The minimental state examination. Arch Gen Psychiatry. 1983;40:812.

  19. Buoen C, Bjerrum OJ, Thomsen MS. How fi rsttime- in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. J Clin Pharmacol. 2005 Oct;45(10):1123–36.

  20. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Guideline on strategies to identify and mitigate risks for fi rst-in-human and early clinical trials with investigational medicinal products. Draft [Internet]. London: European Medicines Agency Committee for Medicinal Products for Human Use (CHMP); 2016 Nov 15 [cited 2020 May 5]. 22 p. Available at: https://www.ema.europa .eu/en/documents/scientific-guideline/draft -guideline-strategies-identify-mitigate-risks-first -human-early-clinical-trials-investigational_en.pdf

  21. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010 Apr;99(4):1654–73.

  22. Muñoz-Cernada A, Fernández-Cervera M, García-Rodríguez JC. Factors involved in the design of nasal delivery systems for peptides and proteins. Biotecnol Apl. 2013;30(2):88–96.

  23. Sosa Testé I, García Rodríguez JC, García JD, Santana J, Subirós N, González C. Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacol Online. 2006;1:100–12.

  24. Lagarto A, Bueno V, Guerra I, Valdés O, Couret M, López R, et al. Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid. Exp Toxicol Pathol. 2011 Sep;63(6):563–7.

  25. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and benefi cial. Mol Med. 2002 Aug; 8(8):495–505.

  26. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009 Dec;40(12):e647–56.

  27. Center for Drug Evaluation and Research (CDER). Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers [Internet]. Washington, D.C.: Department of Health and Human Services; Food and Drug Administration (FDA); 2005 [cited 2020 Apr 21]. 27 p. Available at: https://www.fda.gov/ media/72309/download

  28. Sosa Testé I, Megana Tamos Y, Rodríguez Cruz Y, Muñoz Cernada A, Cruz Rodríguez J, Subirós Martínez N, et al. Dose effect evaluation and therapeutic window of the Neuro-EPO nasal application for the treatment of the focal ischemia model in the Mongolian gerbil. Sci World J. 2012;2012:607498. DOI: 10.1100/2012/607498

  29. Reglamento para la vigilancia de productos farmacéuticos de uso humano durante la comercialización. Resolución 69/2019 [Internet]. Havana: Center for State Control of Medicines, Equipment and Medical Devices (CECMED); 2019 [cited 2020 May 18]. 49 p. Available at: https://www.cecmed.cu/sites/default/fi les/ adjuntos/Reglamentacion/Res.No_.69.2019%20 Peq.pdf. Spanish.

  30. De Cos MA, Flórez J. Reacciones Adversas de los Medicamentos. In: Flórez J, editor. Farmacología Humana. 3rd ed. Barcelona: Masson; 1998. p. 155–64. Spanish.

  31. The use of the WHO-UMC system for standardized case causality assessment [Internet]. Uppsala (SW): The Uppsala Monitoring Center; [date unknown; cited 2020 Apr 21]. 2 p. Available at: http://www.who.int/medicines/areas/quality _safety/safety_effi cacy/WHOcausality_assess ment.pdf

  32. Declaración de Helsinki de La Asociación Médica Mundial. Principios éticos para las investigaciones médicas en seres humanos. Fortaleza: 64ª Asamblea General [Internet]. Pamplona (SP): Universidad de Navarra, Centro de Documentación de Bioética; 2013 [updated 2013 Oct; cited 2019 Jul 23]. 7 p. Available at: http://www.redsamid.net/archivos/201606/2013 -declaracion-helsinki-brasil.pdf?1. Spanish.

  33. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry [Internet]. 2004 Apr [cited 2020 Apr 21];75(4):637–9. Available at: https://doi .org/10.1136/jnnp.2003.020982

  34. Pringsheim T, Jette N, Frolkis A, Steeves TDL. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Move Disord [Internet]. 2014 [cited 2020 21];29(13):1583–90. Available at: https://doi .org/10.1002/mds.25945

  35. Lombardero M, Kovacs K, Scheithauer BW. Erythropoietin: a hormone with multiple functions. Pathobiology [Internet]. 2011 [cited 2020 Mar 18];78(1):41–53. Available at: https:// doi.org/10.1159/000322975

  36. Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. Eur J Clin Invest. 2003 Oct;33(10):891–6.




2020     |     www.medigraphic.com